Publicacións nas que colabora con ERNESTO CANO RUBIO (8)

2017

  1. 3-Oxopyridazin-5-yl-Chalcone Hybrids: Potent Antiplatelet Agents That Prevent Glycoprotein IIb/IIIa Activation

    ChemistrySelect, Vol. 2, Núm. 17, pp. 4920-4933

2012

  1. Discovery and preliminary SAR of 5-arylidene-2,2-dimethyl-1,3-dioxane-4,6- diones as platelet aggregation inhibitors

    Combinatorial Chemistry and High Throughput Screening, Vol. 15, Núm. 7, pp. 551-554

2008

  1. 2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: Design, synthesis, and SAR studies

    Bioorganic and Medicinal Chemistry Letters, Vol. 18, Núm. 2, pp. 793-797

2007

  1. Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity

    Journal of Medicinal Chemistry, Vol. 50, Núm. 26, pp. 6476-6484

2006

  1. Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells

    Neuropharmacology, Vol. 51, Núm. 4, pp. 923-932

  2. Pyridazines part 41: Synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl) pyridazin-3(2H)-ones

    Bioorganic and Medicinal Chemistry Letters, Vol. 16, Núm. 4, pp. 1080-1083

2004

  1. Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones

    Bioorganic and Medicinal Chemistry Letters, Vol. 14, Núm. 2, pp. 321-324

2002

  1. Pyridazines. Part 28: 5-Alkylidene-6-phenyl-3(2H)-pyridazinones, a new family of platelet aggregation inhibitors

    Bioorganic and Medicinal Chemistry Letters, Vol. 12, Núm. 12, pp. 1575-1577